<DOC>
	<DOCNO>NCT02609477</DOCNO>
	<brief_summary>This study evaluate abuse potential single-doses istradefylline compare placebo phentermine recreational stimulant user . Subjects participate outpatient medical Screening visit , 5-day Qualification ( Drug Discrimination ) Phase , 6-period Treatment Phase , outpatient safety Follow-Up visit . Study approximately 25 week total . Within 28 day Screening visit , eligible subject admit CRU ( Day -1 ) Qualification Phase . During Qualification Phase , subject receive single oral dos phentermine 60 mg match placebo randomize , double blind , crossover manner , drug administration separate approximately 48 hour ( Day 1 Day 3 ) , ensure discriminate show positive subjective effect active control . Following evaluation eligibility , subject may discharge ( fail Qualification criterion ) remain CRU ( pas criterion eligible ) proceed directly Treatment Phase . The washout interval last drug administration Qualification Phase first drug administration Treatment Phase least 96 hour ( 4 day ) . Following confirmation eligibility Qualification Phase , subject randomize one 6 treatment sequence accord 6x6 Williams square . Subjects receive single oral dos 6 treatment randomize , double-blind , crossover manner , Istradefylline 40 mg , Istradefylline 80 mg , Istradefylline 160 mg , Phentermine 45 mg , Phentermine 90 mg , Placebo . Each drug administration separate least 21 day . Serial pharmacodynamic evaluation conduct 24 hour study drug administration confirm exposure istradefylline .</brief_summary>
	<brief_title>A Study Evaluate Abuse Potential Istradefylline</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>Subjects provide write informed consent Healthy volunteer , male female 18 55 year age , inclusive Subjects body mass index ( BMI ) within 18.0 33.0 kg/m2 , inclusive Subjects recreational drug user Subjects alcohol substance dependence within 12 month Subjects ever treatment substance use disorder Subjects consume average 5 serving caffeinated beverage per day Subjects history presence clinically significant cardiovascular disease Subject hyperthyroidism glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Recreational stimulant user</keyword>
	<keyword>Recreational Drug Users</keyword>
</DOC>